Glucagon-Like Peptide-1 (Glp-1) Analogs Market, Glucagon-Like Peptide-1 (Glp-1) Analogs Market Size, Glucagon-Like Peptide-1 (Glp-1) Analogs Market Share, Glucagon-Like Peptide-1 (Glp-1) Analogs Market Outlook,

Glucagon-Like Peptide-1 (Glp-1) Analogs Market Is
Booming Across the Globe Explored in Latest
Research 2018-2026
Glucagon-Like Peptide-1 (Glp-1) Analogs Market by Drug Type (Exenatide,
Liraglutide, Lixisenatide, Dulaglutide, Semaglutide, and Albiglutide), by
Distribution Channel (Retail pharmacy and Hospital pharmacy) and by
Geography - Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018 – 2026
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated
for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of
GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release
(which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss
from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
medications. Also, GLP-1 analogs provide weight reduction benefit.
High prevalence of diabetes in the U.S. and Asia-Pacific is expected to drive the growth of
Glucagon-like peptide-1 analogs market
According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million
patients are suffering from diabetes worldwide. According to World Health Organization (WHO) report
2017, diabetes is one of top three cause of death among the non-communicable diseases. China (114.4
million), India (72.9 million) and U.S. (30.2 million) are top three economies having high prevalence
of diabetes. Such high number of prevalence would offers an immense growth opportunity to the GLP1 analogs market. This is also from the fact that approximately 212.4 million people worldwide are
with undiagnosed diabetes.
According to the International Diabetes Federation (IDF), the U.S. has highest prevalence of diabetes
(13% of population), which is expected to drive the growth of glucagon-like peptide-1 analogs market,
owing to cost effectiveness and high penetration of these product in market. GLP-1 analogs not only
act in type-2 diabetes but also in type 1 diabetes with almost nil hypoglycemic effect, according to the
study published in the Journal of American Health and Drug Benefit. According to study published in
journal Obesity Review (2017), GLP-1 analogs aid in weight reduction of diabetic as well as nondiabetic obese patient. GLP-1 analog liraglutide is already approved in treating obese and overweight
patient, which is expected to fuel the growth of the GLP-1 analogs market.
Get The PDF Brochure of This Business Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1252
Increasing awareness amongst physicians regarding benefits of GLP-1 analogs over conventional
anti-diabetic medication is propelling the growth of the market.
GLP-1 analogs are administered through subcutaneous injection with the help of injectable pen, which
are relatively expensive (US$ 492 for 30-day therapy) as compared to conventional type-2 diabetes
medication such as insulin sensitizers and secretagogues (US$ 5-9 for 30-day therapy) which is the
major factor restraining growth of the market. Also, there is an issue of patient compliance. For
instance, GLP-1 analogs need to be administered through injection as compared to other anti-diabetic
medications, which are taken orally in tablet form.
Key players operating in the global Glucagon-like peptide-1 analogs market include Novo Nordisk, EliLilly and Company, Sanofi, AstraZeneca plc, GlaxoSmithKline plc F., Hoffmann-La Roche Ltd.
Exenatide is the first GLP-1 analog approved in 2005, marketed by AstraZeneca under brand names
Byetta and Byedureon Bcise. Its patent expired in October 2017. Teva got approval to commercialize
the generic version of Byetta and its abbreviated new drug application is under FDA review. Novo
Nordisk in October 2017 received FDA approval for once-a-week GLP-1 analog semaglutide. GSK
announced to discontinue the global sale of albiglutide brand Tanzeum, Eperzan from July 2018 due to
low profits.
Ask For Sample Copy of This Business Report :
https://www.coherentmarketinsights.com/insight/request-sample/1252
Taspoglutide is a molecule being developed by Roche targeting once a week dosing as against daily
dosing regimen of other GLP-1 analogs. However, in 2016 it decided to halt clinical development due
to high gastrointestinal side effects and hypersensitivity reactions.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level.

Download Report